ReviewScience translational medicine2014
Imaging and nanomedicine in inflammatory atherosclerosis.
Review in Science translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed.
- Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration.Nanomedicine : nanotechnology, biology, and medicine · 2015Trial
- A hierarchical theranostic nanoagent for multimodal imaging and targeted foam cell intervention in atherosclerosis.Nature communications · 2026Article
- Nanoparticle to Nanoparticle Bioorthogonal Detection of Atherosclerosis.ACS applied materials & interfaces · 2025Article
- Resolvin D1 delivery to lesional macrophages using antioxidative black phosphorus nanosheets for atherosclerosis treatment.Nature nanotechnology · 2024Article
- The biological applications of near-infrared optical nanomaterials in atherosclerosis.Journal of nanobiotechnology · 2024Review
- Tailored Viral-like Particles as Drivers of Medical Breakthroughs.International journal of molecular sciences · 2024Review
- Oxidative stress biomarker triggered multiplexed tool for auxiliary diagnosis of atherosclerosis.Science advances · 2023Article
- A Comparative Study of Ultrasmall Calcium Carbonate Nanoparticles for Targeting and Imaging Atherosclerotic Plaque.ACS nano · 2023Article
- Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis.Nature communications · 2022Article
- Ultrabright Föster Resonance Energy Transfer Nanovesicles: The Role of Dye Diffusion.Chemistry of materials : a publication of the American Chemical Society · 2022Article
- Osteopontin-Targeted and PPARδ-Agonist-Loaded Nanoparticles Efficiently Reduce Atherosclerosis in Apolipoprotein EACS omega · 2022Article
- Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.Nature reviews. Cardiology · 2022Review
- Development of Molecular Magnetic Resonance Imaging Tools for Risk Stratification of Carotid Atherosclerotic Disease Using Dual-Targeted Microparticles of Iron Oxide.Translational stroke research · 2022Article
- Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Designer Functional Nanomedicine for Myocardial Repair by Regulating the Inflammatory Microenvironment.Pharmaceutics · 2022Review
- Nanotechnology for cardiovascular diseases.Innovation (Cambridge (Mass.)) · 2022Review
- Nanoconfined anti-oxidizing RAFT nitroxide radical polymer for reduction of low-density lipoprotein oxidation and foam cell formation.Nanoscale advances · 2022Article
- Intravital Microscopy in Atherosclerosis Research.Methods in molecular biology (Clifton, N.J.) · 2022Article
- ROS-responsive biomimetic nanoparticles for potential application in targeted anti-atherosclerosis.Regenerative biomaterials · 2021Article
- A Nano-Emulsion Platform Functionalized with a Fully Human scFv-Fc Antibody for Atheroma Targeting: Towards a Theranostic Approach to Atherosclerosis.International journal of molecular sciences · 2021Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Bioengineering provides unique opportunities to better understand and manage atherosclerotic disease. The field is entering a new era that merges the latest biological insights into inflammatory disease processes with targeted imaging and nanomedicine. Preclinical cardiovascular molecular imaging allows the in vivo study of targeted nanotherapeutics specifically directed toward immune system components that drive atherosclerotic plaque development and complication. The first multicenter trials highlight the potential contribution of multimodality imaging to more efficient drug development. This review describes how the integration of engineering, nanotechnology, and cardiovascular immunology may yield precision diagnostics and efficient therapeutics for atherosclerosis and its ischemic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.